⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Figure S12 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

H. Josh Jang Galen Hostetter Alexander W. Macfarlane Zachary Madaj Eric A. Ross Toshinori Hinoue Justin R. Kulchycki Ryan S. Burgos Mahvish Tafseer R. Katherine Alpaugh Candice L. Schwebel Rutika Kokate Daniel M. Geynisman Matthew R. Zibelman Pooja Ghatalia Peter W. Nichols Woonbok Chung Jozef Madžo Noah M. Hahn David I. Quinn Jean‐Pierre J. Issa Michael J. Topper Stephen B. Baylin Hui Shen Kerry S. Campbell Peter A. Jones Elizabeth R. Plimack

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 12: HLA-DR and NKG2D abundance on peripheral lymphocytes associate with longer progression free survival.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jang et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db643587523a04 https://doi.org/10.1158/1078-0432.27030442.v1

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S9 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy2024
2Figure S8 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy2024
3Figure S10 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy2024
4Figure S11 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy2024
5Figure S7 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy2024

More related papers

Figure S1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy2024
Figure S6 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy2024
Figure S4 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy2024